Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
33
Number of overlapping holdings
10.2%
% of FHLC's 349 holdings also in CANC
68.8%
% of CANC's 48 holdings also in FHLC
Overlap by Weight
Sector Drift (FHLC minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in FHLC |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
ELI LILLY & CO | 11.3% | 5.3% | 5.3% |
|
MERCK & CO. INC. | 3.8% | 2.9% | 2.9% |
|
AMGEN INC | 2.8% | 2.9% | 2.8% |
|
ABBVIE INC | 6.1% | 2.1% | 2.1% |
|
BRISTOL-MYERS SQUIBB CO | 2.0% | 4.5% | 2.0% |
Position Highlights (Non-Overlapping Exposures)
FHLC Overweight Relative to CANC
|
UNITEDHEALTH GROUP INC | 7.3% |
|
JOHNSON & JOHNSON | 6.4% |
|
ELI LILLY & CO | 5.9% |
|
ABBVIE INC | 4.0% |
|
ABBOTT LABORATORIES | 3.8% |
|
THERMO FISHER SCIENTIFIC INC | 3.3% |
|
INTUITIVE SURGICAL INC | 3.0% |
|
PFIZER INC | 2.4% |
|
BOSTON SCIENTIFIC CORP | 2.3% |
|
DANAHER CORP | 2.2% |
FHLC Underweight Relative to CANC
|
REVOLUTION MEDICINES, INC. | -5.3% |
 |
ROCHE HOLDINGS LTD-SPONS ADR | -5.2% |
 |
ASTRAZENECA PLC | -4.3% |
|
NOVARTIS AG | -4.2% |
|
BRIDGEBIO PHARMA, INC. | -4.1% |
|
EXELIXIS INC | -3.9% |
|
NUVALENT, INC. CLASS A | -3.7% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.7% |
 |
GENMAB A/S SPONSORED ADR | -3.1% |
 |
MERUS N.V. | -3.1% |